This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Ondexxya
  • /
  • A Study in Older Subject to Evaluate the Safety an...
Clinical trial

A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban

Read time: 1 mins
Last updated:30th Sep 2018
Status: Completed
Identifier: NCT02220725
A Study in Older Subject to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Rivaroxaban


The purpose of this study is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Rivaroxaban.


Study Type: Interventional  (Clinical Trial)
Actual Enrollment: 80 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study in Older Subjects to Assess Safety and the Reversal of Rivaroxaban Anticoagulation With Intravenously Administered Andexanet Alpha
Study Start Date: May 2014
Actual Primary Completion Date: August 2015
Actual Study Completion Date: August 2015

Arms:
- Experimental:
Andexanet
- Placebo Comparator: Placebo

Category Value
Study type(s) Interventional
Actual enrolment 80
Study start date 01 May 2014
Actual primary completion date 01 August 2018

View full details